Gradientech publishes prospectus
The Board of Directors of Gradientech AB (publ) (“Gradientech” or “the Company”) decided on 26 February 2026 to carry out a new issue of shares with preferential rights for existing shareholders of approximately SEK 57 million (the “Rights Issue”). A prospectus regarding the Rights Issue is approved by the Swedish Financial Supervisory Authority and is available on the Company's website gradientech.se (https://gradientech.se/investors/).
Prospectus
Complete terms and conditions for the Rights Issue as well as other information about the Company and information about subscription commitments appear in the prospectus that is available on the Company’s and the Swedish Financial Supervisory Authority respective websites (gradientech.se, fi.se).
Investor presentations
Shareholders are invited to participate in Gradientech’s investor presentations via Teams at the following times:
11 March, 11.00-11.30 CET
12 March, 17.00-17.30 CET
16 March, 15.00-15.30 CET
Links to the presentation events are available on the Company’s website gradientech.se.
For further information, please contact:
Sara Thorslund, CEO
Urban Adolfsson, CFO
Tel: + 46 708 20 72 09
About Gradientech
Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our innovative diagnostic solutions aim to save lives, reduce healthcare costs, and combat the spread of antibiotic resistance – one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit gradientech.se for more information.